|
|
|
|
LEADER |
04776nam a22005175i 4500 |
001 |
17255 |
003 |
DE-He213 |
005 |
20130727061752.0 |
007 |
cr nn 008mamaa |
008 |
130217s2013 ne | s |||| 0|eng d |
020 |
# |
# |
|a 9789400757998
|9 978-94-007-5799-8
|
024 |
7 |
# |
|a 10.1007/978-94-007-5799-8
|2 doi
|
050 |
# |
4 |
|a R-RZ
|
072 |
# |
7 |
|a MBGR
|2 bicssc
|
072 |
# |
7 |
|a MED000000
|2 bisacsh
|
082 |
0 |
4 |
|a 610
|2 23
|
100 |
1 |
# |
|a Ritsner, Michael S.
|e editor.
|
245 |
1 |
0 |
|a Polypharmacy in Psychiatry Practice, Volume II
|b Use of Polypharmacy in the "Real World" /
|c edited by Michael S. Ritsner.
|h [electronic resource] :
|
264 |
# |
1 |
|a Dordrecht :
|b Springer Netherlands :
|b Imprint: Springer,
|c 2013.
|
300 |
# |
# |
|a XVII, 321 p. 2 illus., 1 illus. in color.
|b online resource.
|
336 |
# |
# |
|a text
|b txt
|2 rdacontent
|
337 |
# |
# |
|a computer
|b c
|2 rdamedia
|
338 |
# |
# |
|a online resource
|b cr
|2 rdacarrier
|
347 |
# |
# |
|a text file
|b PDF
|2 rda
|
505 |
0 |
# |
|a 1. Antipsychotic polypharmacy for schizophrenia: 'Secret sauce' or 'wild abandon'? -- Antipsychotic polypharmacy in USA -- Antipsychotic polypharmacy in Czech Republic and in Ukraine -- Antipsychotic polypharmacy in residential facilities in Italy: the gap between recommendations and real world practice -- Antipsychotic polypharmacy and associated phenomena in patients with schizophrenia: Rational or irrational? -- Antipsychotic polypharmacy in schizophrenia. How to counteract this common practice? -- Clozapine combinations in treatment-resistant schizophrenia patients -- Metabolic syndrome and antipsychotic polypharmacy -- Evidence based combination therapy for bipolar disorder -- Antidepressant combination�strategies for major depressive disorder -- Herbal remedies and nutraceuticals as augmentation or adjunct for mood and anxiety disorders: evidence for benefit and risk -- Obsessive-compulsive syndromes in schizophrenia: A case for polypharmacy? -- Polypharmacy and potentially inappropriate medication use among elders with dementia -- The role of polypharmacy in bipolar disorder treatment guidelines.
|
520 |
# |
# |
|a Despite the large number of psychotropic medications currently available, effective management of mental disorders continues to be a challenging task. Although monotherapy may be desirable, most patients require combinations of two or more psychotropic drugs. Polypharmacy aims to address different aspects of treatment resistance, especially insufficient response of positive and negative symptoms, cognitive disturbances, affective comorbidity, obsessive-compulsive syndromes and side-effects of antipsychotic agents. At the same time, evidence based guidelines in support of polypharmacy, and augmentative strategies are scant. This two-volume collection is the first comprehensive, clinically oriented, reference text on polypharmacy (co-administration of more than one medication) or the use of multiple preparations to treat psychotic, cognitive, mood and anxiety disorders. This�collection is divided into four parts. Volume I contains two parts including chapters that serve as an introduction and overview of conceptual issues. Key topics include: rational polypharmacy, receptor binding targets, drug interactions, preclinical and clinical investigations in this field, dosing regimens, multiple medication use in forensic psychiatry, a naturalistic trial, adjunctive strategies, and multiple medication use for the treatment of somatic symptom disorders. Volume II contains two parts that focus on antipsychotic polypharmacy for schizophrenia, and clinical practice in the USA, Czech Republic, Ukraine, and Italy, polypharmacy and associated phenomena, clozapine combinations and the metabolic syndrome. The authors discuss combination therapy for bipolar disorder, major depressive disorder, obsessive-compulsive syndromes in schizophrenia, and potentially inappropriate medication use among elderly patients with dementia. Finally, each volume includes Appendix contains Annotated bibliography on polypharmacy and List of Psychotropic Medications .
|
650 |
# |
0 |
|a Medicine.
|
650 |
# |
0 |
|a Pharmacy.
|
650 |
# |
0 |
|a Psychiatry.
|
650 |
# |
0 |
|a Psychopharmacology.
|
650 |
# |
0 |
|a Medical Education.
|
650 |
# |
0 |
|a Psychology, clinical.
|
650 |
1 |
4 |
|a Biomedicine.
|
650 |
2 |
4 |
|a Biomedicine general.
|
650 |
2 |
4 |
|a Psychiatry.
|
650 |
2 |
4 |
|a Pharmacy.
|
650 |
2 |
4 |
|a Clinical Psychology.
|
650 |
2 |
4 |
|a Medical Education.
|
650 |
2 |
4 |
|a Psychopharmacology.
|
710 |
2 |
# |
|a SpringerLink (Online service)
|
773 |
0 |
# |
|t Springer eBooks
|
776 |
0 |
8 |
|i Printed edition:
|z 9789400757981
|
856 |
4 |
0 |
|u https://ezaccess.library.uitm.edu.my/login?url=http://dx.doi.org/10.1007/978-94-007-5799-8
|
912 |
# |
# |
|a ZDB-2-SBL
|
950 |
# |
# |
|a Biomedical and Life Sciences (Springer-11642)
|